ODYSSEE Kidney Health Trial

Chronic Kidney Diseases Clinical Trial

— ODYSSEE-KH  

Official title:

Open Access Digital CommunitY Promoting Self-Care, Peer Support, and HEalth LitEracy (ODYSSEE) for Kidney Health (KH) Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06274710
• Other study ID #: 23-5554
• Status: Recruiting
• Phase: N/A
• Start date: December 13, 2023
• Est. completion date: April 13, 2026

Study information

• Verified date: February 2024
• Source: University Health Network, Toronto
• Contact: Robert Nolan, PhD
• Phone: (416) 340-4800
• Email: rob.nolan[@]uhn.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

INTRODUCTION

Severe CKD is defined as a risk of greater than 10% for progressing to RRT [home hemodialysis (HHD), home peritoneal dialysis (HPD), and transplantation] within 2 years. There is a need to improve access to CKD self-care counselling and RRT education for patients with severe CKD. Trials of CKD self-care education have achieved therapeutic benefits with moderate to high patient-provider contact. There is high potential for a trial of digital counselling for CKD self-care and RRT education to enhance patient health and quality of life.

HYPOTHESES

The primary hypothesis is that ODYSSEE-KH versus usual care (UC) will significantly increase the incidence of home RRT, measured by a composite index of HHD, HPD, and preemptive kidney transplant at trial completion (median = 19 months; range: 12 to 27 months).

The secondary hypothesis is that ODYSSEE-KH for CKD self-care and RRT education improves Home RRT, RRT preparation, annual hospitalization rate, engagement with CKD self-care resources at months 6 and 12 and trial completion and scores on outcome measures.

RECRUITMENT

Patients diagnosed with CKD who are 18 years of age or older were recruited from University Health Network (UHN), Sunnybrook Hospital, Scarborough Health Network, and The Ottawa Hospital.

DESIGN

ODYSSEE-KH is a double-arm, parallel-group, randomized controlled trial that has assessments at baseline, months 6 and 12, and trial completion (median = 19 months; range: 12 to 27 months). This is a single-blind design with research personnel masked.

ODYSSEE-KH combines automated digital counselling of CKD self-care with renal replacement therapy (RRT) education. UC enhances the standard of usual care by providing patients with conventional digital CKD education. Over 27 months, patients will be emailed on a weekly basis with a digital link to log on to their respective program using a password-protected, personal account.

ANALYSIS

Separate GLMs will evaluate if Digital Counselling versus UC is independently associated with outcomes at months 6 and 12 and trial completion (median = 19; range: 12 to 27 months). Dependent variables include the KDQOL-SF, SF-36, EUROIA, PHQ-9, GAD-7, MIDLS, ESSI, PWB, BMPN, AI, as well as a modified SEMCD-6. Multivariable models will adjust for baseline assessments of each outcome and potential baseline covariates (noted above). In all GLMs, significant interactions will be followed by subgroup analyses with Bonferroni post hoc tests.

Description:

BACKGROUND

In Canada, severe CKD prevalence is 14.9 per 1000 persons. The mortality risk is greatest for pre-dialysis patients with stage 4 or 5 CKD (182 deaths per 1000). The annual cost of medical services for Canadians with CKD is $32 billion, with an annual cost per patient of $20 124 and $23 303 at stages 4 and 5, respectively. Persons with stage 4 or 5 CKD also report a lower quality of life and experience the greatest decrement in quality-adjusted life years projected over time.

Kidney transplantation is recognized as the gold standard for RRT due to its benefit for improving clinical outcomes and quality of life. However, the median wait time in Canada for kidney transplantation is 4 years. Approximately 80% of patients with severe CKD are suitable to receive dialysis. Most CKD patients (76%) receive in-center hemodialysis (ICHD), while only 17% receive home hemodialysis (HHD) and 2.5% receive home peritoneal dialysis (HPD). When considering the systemic and patient burden of CKD, it is important to note that ICHD does not offer added survival benefits, and patients who receive home dialysis report greater quality of life. There is also a lower cost for providing HHD and HPD versus ICHD.

Task force statements and reviews advocate for informed patient choice about HHD and HPD, and patients who receive RRT education are more likely to select home dialysis. However, 38% of CKD patients on dialysis report that they were not informed or involved in the decision to select their dialysis modality, and 64% report that education on managing CKD was inadequate or not provided. During the SARS-CoV-2 pandemic, in-hospital dialysis was associated with a 3- to 4-fold increased risk of virus infection and a high mortality rate of 21-34%, which further supports HHD and HPD.

Task force committees concede that patients with severe CKD require specialized nephrology services that include (i) education to promote informed decision-making about RRT and (ii) counselling to improve quality of life and CKD self-care (i.e., attending medical appointments and adhering to medications, dialysis, fluid and dietary guidelines, monitoring symptoms, engaging in an active lifestyle, and refraining from smoking). A Cochrane review of 40 longitudinal cohort studies (pooled N = 63 887) reported that early access to specialized services predicted shorter hospitalization for initial admission [-9.1 days; 95% confidence interval (CI): -11 to -7], and reduced mortality at 12 months (RR =0.65; 95% CI: 0.62 to 0.69) and 5 years (RR = 0.66; 95% CI: 0.60 to 0.71). Corroborating findings from a meta-analysis (pooled N = 648) and a recent randomized trial (N = 130) show that CKD self-care education with telehealth services is associated with reduced hospital admissions and emergency department visits. A further meta-analysis (pooled N = 1647) reported improved quality of life with CKD self-care education or counselling. It is, therefore, vital to commence a CKD self-care and RRT initiative that is evidence-based, scalable, and patient-centred.

RATIONALE

Trials of CKD self-care education have achieved therapeutic benefits with moderate to high patient-provider contact. Direct contact time with individual patients has been estimated in a systematic review of behavioural counselling to range up to 6 hours, which limits the scalability of conventional programs. Moreover, current CKD patient education programs are infrequent and not standardized. CKD patients have reported in several studies that they are not adequately informed or involved in decision-making about their care. In addition, patient barriers that influence informed decision-making about home-based RRT are not adequately addressed. Importantly, patients with severe CKD express marked interest in counselling that extends beyond information about procedures or medical outcomes. Patient interests include ways to improve quality of life and psychosocial well-being, control of care, safety, ability to maintain daily activities, and communication with health care providers. There is high potential for a trial of digital counselling for CKD self-care and RRT education to enhance patient health and quality of life. The risk for mortality decreases in a stepwise manner with incremental adherence to self-care[PR1] . A digital strategy is feasible to promote CKD self-care since 90% of Canadians report internet access, which includes 81 to 93% of persons in the 2 lowest income quartiles, 87% of individuals aged 50 to 64 years, and 66% of those equal to or greater than 65 years.

HYPOTHESES

The primary hypothesis is that ODYSSEE-KH versus UC will significantly increase the incidence of home RRT, measured by a composite index27 of HHD, HPD, and preemptive kidney transplant at trial completion (median = 19 months; range: 12 to 27 months).

The secondary hypothesis is that ODYSSEE-KH versus UC will significantly improve the following:

1. Home RRT (composite index of HHD, HPD, and preemptive kidney transplant at trial completion)27

2. RRT preparation [incidence of arteriovenous fistula (AVF) or arteriovenous graft (AVG), or PD catheter] at trial completion (median = 19 months; range: 12 to 27 months)

3. Annual hospitalization rate, calculated as a rate per patient per year, at trial completion (median = 19 months; range: 12 to 27 months)

4. Engagement with CKD self-care resources at months 6 and 12 and trial completion (median = 19 months; range: 12 to 27 months), defined by the sum of logon minutes, the sum of logons, and the number of logon days prior to a lapse of equal to or greater than 2 months (taken from CHF-CePPORT49-52 and the former pilot study).

5. The following patient-reported outcome measures of HRQL at baseline, months 6 and 12, and trial completion (median = 19 months; range: 12 to 27 months):

• HRQL (KDQOL-SF and SF-36)

• Engagement in activities for living well (EUROIA)

• Depression (PHQ-9)

• Anxiety (GAD-7)

• Mattering in life domains (MIDLS)

• Social support (ESSI)

• Psychological well-being (PWB)

• Psychological needs (BMPN)

• Extrinsic and intrinsic aspirations (AI)

• Self-efficacy in managing a chronic disease (SEMCD-6)

POTENTIAL RISKS

There is a potential risk that patients in the intervention arm will feel uncomfortable while using ODYSSEE-KH because they are not familiar with the software. Participants may also feel uncomfortable answering certain questions posed in the questionnaire packages, such as those pertaining to mental health, social support, loneliness, and disease burden.

SAFETY PARAMETERS

This is a non-invasive, digital (behavioural) counselling trial. It is complementary in nature and patients will be aware that they can withdraw at any time based on the informed consent procedure. Therefore, there are no significant safety issues associated with this trial.

Personal accounts on the ODYSSEE program will be password-protected. The website itself is hosted on the secure UHN server.

Some of the items presented in the self-report measures of HRQL pertain to mental, physical, social, and occupational functioning. If participants have any concerns about answering one or more questions posed in the questionnaire package, they may contact our office by email or telephone so that their concerns may be addressed. A refusal to respond to any questionnaire item will be accommodated for.

STATISTICAL PLAN

A time-to-event analysis at trial completion (median = 19; range: 12 to 27 months) will be performed using a multivariable Cox Proportional Hazards (PH) model. It will evaluate if Digital Counselling versus UC significantly improves the likelihood for home-based RRT, based on a composite endpoint of first of HPD, HHD, or preemptive kidney transplant. Potential confounders (e.g., age, gender) will be selected using forward (p < 0.05) and backward (p < 0.10) stepwise selection.

A multivariable Cox PH model will assess if Digital Counselling versus UC significantly improves the likelihood for the composite endpoint of incidence of AVF, or AVG, or PD catheter at trial completion (median = 19; range: 12 to 27 months).

At trial completion (median = 19; range: 12 to 27 months), log-linear Poisson models will be conducted for hospitalization rate, per patient, per year. A multivariable Cox PH model will then evaluate if Digital Counselling versus UC significantly increases time to hospitalization.

Separate Generalized Linear Models (GLMs) will evaluate if Digital Counselling versus UC evokes greater CKD self-care program adherence at months 6 and 12- and trial completion (median = 19; range: 12 to 27 months). The dependent variable will be the sum of logon time and the predictors will include age, gender, and trial arm (Digital Counselling or UC), as well as potential baseline confounders (noted above). The GLM for the endpoints will be repeated using the sum of logons as the dependent variable. Finally, for these endpoints, a multivariable Poisson model will evaluate whether Digital Counselling versus UC is associated with greater duration of engagement (defined as the sum of logons, sum of logon hours, and number of logon days prior to a logon lapse of equal to or greater than 1 month), adjusting for sex, age, and potential confounding variables (noted above).

Separate GLMs will evaluate if Digital Counselling versus UC is independently associated with outcomes at months 6 and 12 and trial completion (median = 19; range: 12 to 27 months). Dependent variables include the KDQOL-SF, AI, EUROIA, ESSI, PHQ-9, GAD-7, BMPN, PWB, MIDLS and SF-36, as well as a modified SEMCD-6. Multivariable models will adjust for baseline assessments of each outcome and potential baseline covariates (noted above). In all GLMs, significant interactions will be followed by subgroup analyses with Bonferroni post-hoc tests.

After testing interactions between Digital Counselling versus UC and gender in the primary and secondary outcome analyses, separate exploratory analyses will be performed for gender categories sufficiently represented in the sample. Separate competing risk models will be employed to evaluate time to each of the following outcomes: HPD, HHD, and preemptive kidney transplant.

DEVIATIONS FROM STATISTICAL PLAN

A need to deviate from the original statistical plan is not anticipated because exploratory analyses are included. Nevertheless, the Statistical Analyses and Methodology Committee will be consulted regularly throughout the trial.

SAMPLE SIZE

The sample estimate for the ODYSSEE-KH trial, with monitoring over 19 months, is only 64 patients, type 1 error = 5% and power = 80%.The CKD pilot study achieved moderate program adherence, similar to the CHF-CEPPORT trial whereby the median proportion of sessions access was 61%. The sample estimate to detect this effect with a double-group design, type 1 error of 5%, and power of 80% is N = 114. In sum, the conservative sample estimate used for our primary outcome will ensure appropriate statistical power to evaluate our secondary outcomes of hospitalization and usability. The final sample estimate is N = 344, with a type 1 error of 5% and a power of 80%.

COMPLIANCE

Participation will be supported by senior clinical staff members to ensure that trial activities are presented as complementary to a patient's healthcare. The research team will promote adherence to online assessments via REDCap® with email, telephone, and in-person reminders.

WITHDRAWAL

This trial does not include invasive procedures or changes to medications that could trigger a significant clinical event. Therefore, the need to actively withdraw subjects from this complementary, behavioural (digital) counselling program is not anticipated.

CRITERIA FOR TRIAL TERMINATION

The ODYSSEE-KH trial would have been terminated prematurely in the event of a recurrent adverse event that was related to our trial procedures or content.

QUALITY CONTROL AND ASSURANCE

Daily management and monitoring of recruitment and assessment activities will be completed by the research coordinator.

Responsibility for quality control will remain with the full team. The multidisciplinary research team holds senior administrative, clinical, and research appointments at participating institutions

CONSENT

Initial contact with the patient will be made only by members of the circle of care, who will not attempt to obtain informed consent from the patients. Clinical staff in participating outpatient nephrology clinics will identify patients who meet trial criteria and will obtain verbal consent to be approached by the research team. Informed consent will be obtained either in person or virtually. Regardless of the method, A follow-up email will be sent to the participant by the research team containing the participant's onboarding information (i.e., hyperlink to ODYSSEE platform, username, and temporary password), as well instructions and tutorial videos on how to access the ODYSSEE platform.

In-person, a trained research team member will approach the potential participant during their clinic appointment and will provide them with a hard copy of the Informed Consent Form. The trained research team member will discuss the content of the Informed Consent Form with the patient and will address any questions and/or concerns relating to the trial that the patient may have. Patients will be informed that their participation is voluntary and that it will have no bearing on their healthcare. Moreover, this message is clearly conveyed in the Informed Consent Form. The trained research team member will provide the patient with as much time as they require to make an informed decision about participating in the trial.If the patient decides to consent to participate in the trial, informed consent will be obtained in person via double signatures on hard copies. One copy will be kept on file by the research team and the other copy will be retained by the participant.

Virtually, a trained research team member will contact the patient by telephone to confirm their interest in the trial. The trained research team member will email the patient a hyperlink to the Informed Consent Form, housed on the UHN REDCap server ®. The patient will be asked to refrain from signing the Informed Consent Form until they have had an opportunity to discuss the trial, as well as any questions and/or concerns they may have, with the research team. The trained research team member will discuss the content of the Informed Consent Form with the patient over the telephone and will address any questions and/or concerns relating to the trial that the patient may have. Patients will be informed that their participation is voluntary and that it will have no bearing on their healthcare. Moreover, this message is clearly conveyed in the Informed Consent Form. The trained research team member will provide the patient with as much time as they require to make an informed decision about participating in the trial. If the patient decides to consent to participate in the trial, informed consent will be obtained virtually via electronic signatures on PDF copies. A copy will be kept on file by the research team and the other copy will be sent to the participant by email.

DATA STORAGE

All data will be stored on secure servers within the UHN digital environment, ensuring that security measures are well-developed to protect the data from external intrusion. Data will be stored for 10 years as per UHN Research procedure.

The digital forms and materials will be retained on the secure UHN server for at least 10 years from the completion of the trial.

Data will be available from the corresponding author pending approval of research ethics boards of participating institutions and on a reasonable request received from qualified researchers trained in human subject confidentiality protocols.

PRIVACY AND CONFIDENTIALITY

Subjects are issued a tracking number when data involving identifying information is transmitted for analysis. Subject anonymity and confidentiality have been preserved. Only aggregate data will be published.

All research personnel have signed an employee confidentiality agreement ensuring that confidential information is not disclosed to any other person or entity. All source documents containing personal identifiers are stored in filing cabinets under lock and key. The database is stored electronically on the firewall-protected server, making it inaccessible externally. Access to the room containing the research file server is restricted to designated persons who are employed by the Behavioural Cardiology Research Unit at the UHN.

Discussion of the trial with persons outside the research team will never reveal the personal identifiers of participants. All-access to data is denied to persons outside the research team. Data transmission occurs via encrypted storage material over the Internet.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 344
• Est. completion date: April 13, 2026
• Est. primary completion date: April 13, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• CKD patients who are at least 18 years old, that have a greater than a 10% risk of requiring dialysis within 2 years, using the 4-variable 2-year Kidney Failure Risk Equation,1,2 and are registered in a nephrology clinic (including an in-center dialysis clinic) at a participating hospital

• Confirmation from a referring nephrologist that the CKD has been stable for at least 1 month at the time of enrollment

• Oral and written comprehension of English or French

• Informed written consent

• At least a basic level of self-reported computer literacy

• Access to the internet and a computer

Exclusion Criteria:

• Previous kidney transplant or waitlisted for organ transplant at the time of enrollment

• Severe co-morbidities that prohibit full participation (e.g., dementia, clinically severe depression)

• Diagnosis of a medical condition for which the life expectancy is less than 2 years.

Related Conditions & MeSH terms

• Chronic Kidney Diseases
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Behavioral:
• ODYSSEE-KH
Automated digital counselling program

Locations

Country	Name	City	State
Canada	University Health Network	Toronto	Ontario

Sponsors (4)

Lead Sponsor	Collaborator
University Health Network, Toronto	Scarborough General Hospital, Sunnybrook Health Sciences Centre, The Ottawa Hospital

Country where clinical trial is conducted

Canada, 

References & Publications (75)

(CIHI), C. I. f. H. I. About CIHI, <https://www.cihi.ca/en/about-cihi> (

(CIHI), C. I. f. H. I. CIHI, <https://www.cihi.ca/en>

(CIHI), C. I. f. H. I. What is the data request process at CIHI?, <https://www.cihi.ca/en/faq/what-is-the-data-request-process-at-cihi>

Akbari A, Clase CM, Acott P, Battistella M, Bello A, Feltmate P, Grill A, Karsanji M, Komenda P, Madore F, Manns BJ, Mahdavi S, Mustafa RA, Smyth A, Welcher ES. Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management. Am J Kidney Dis. 2015 Feb;65(2):177-205. doi: 10.1053/j.ajkd.2014.10.013. Epub 2014 Nov 4. — View Citation

Andrassy KM. Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int. 2013 Sep;84(3):622-3. doi: 10.1038/ki.2013.243. No abstract available. — View Citation

Authority, C. I. R. Canada's Internet Factbook 2018: Canada's source for current internet data. (2018).

Beishuizen CR, Stephan BC, van Gool WA, Brayne C, Peters RJ, Andrieu S, Kivipelto M, Soininen H, Busschers WB, Moll van Charante EP, Richard E. Web-Based Interventions Targeting Cardiovascular Risk Factors in Middle-Aged and Older People: A Systematic Review and Meta-Analysis. J Med Internet Res. 2016 Mar 11;18(3):e55. doi: 10.2196/jmir.5218. — View Citation

Bello AK, Ronksley PE, Tangri N, Kurzawa J, Osman MA, Singer A, Grill A, Nitsch D, Queenan JA, Wick J, Lindeman C, Soos B, Tuot DS, Shojai S, Brimble S, Mangin D, Drummond N. Prevalence and Demographics of CKD in Canadian Primary Care Practices: A Cross-sectional Study. Kidney Int Rep. 2019 Jan 21;4(4):561-570. doi: 10.1016/j.ekir.2019.01.005. eCollection 2019 Apr. — View Citation

Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006 Apr;12(3):239-45. doi: 10.18553/jmcp.2006.12.3.239. — View Citation

Brunori G, Reboldi G, Aucella F. Lessons Learnt during the COVID-19 Pandemic: For Patients with End-Stage Renal Disease, We Should Prioritize Home-Based Treatment and Telemedicine. Kidney Blood Press Res. 2021;46(1):11-16. doi: 10.1159/000512629. Epub 2021 Jan 29. — View Citation

Center, P. R. Internet/Broadband Fact Sheet, <https://www.pewresearch.org/internet/fact-sheet/internet-broadband/> (2021).

Chan CT, Wallace E, Golper TA, Rosner MH, Seshasai RK, Glickman JD, Schreiber M, Gee P, Rocco MV. Exploring Barriers and Potential Solutions in Home Dialysis: An NKF-KDOQI Conference Outcomes Report. Am J Kidney Dis. 2019 Mar;73(3):363-371. doi: 10.1053/j.ajkd.2018.09.015. Epub 2018 Dec 10. — View Citation

Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005 Nov 1;143(9):659-72. doi: 10.7326/0003-4819-143-9-200511010-00010. — View Citation

Comellas M, Walker EA, Movsas S, Merkin S, Zonszein J, Strelnick H. Training community health promoters to implement diabetes self-management support programs for urban minority adults. Diabetes Educ. 2010 Jan-Feb;36(1):141-51. doi: 10.1177/0145721709354606. Epub 2009 Dec 4. — View Citation

Dahlerus C, Quinn M, Messersmith E, Lachance L, Subramanian L, Perry E, Cole J, Zhao J, Lee C, McCall M, Paulson L, Tentori F. Patient Perspectives on the Choice of Dialysis Modality: Results From the Empowering Patients on Choices for Renal Replacement Therapy (EPOCH-RRT) Study. Am J Kidney Dis. 2016 Dec;68(6):901-910. doi: 10.1053/j.ajkd.2016.05.010. Epub 2016 Jun 21. — View Citation

Eneanya ND, Maddux DW, Reviriego-Mendoza MM, Larkin JW, Usvyat LA, van der Sande FM, Kooman JP, Maddux FW. Longitudinal patterns of health-related quality of life and dialysis modality: a national cohort study. BMC Nephrol. 2019 Jan 8;20(1):7. doi: 10.1186/s12882-018-1198-5. — View Citation

Fadem SZ, Walker DR, Abbott G, Friedman AL, Goldman R, Sexton S, Buettner K, Robinson K, Peters TG. Satisfaction with renal replacement therapy and education: the American Association of Kidney Patients survey. Clin J Am Soc Nephrol. 2011 Mar;6(3):605-12. doi: 10.2215/CJN.06970810. Epub 2011 Feb 17. — View Citation

Fezza, G., Sansone, S., Surikova, J., Ross, H. & Nolan, R. Patient Engagement with an Ecounseling Platform is Enhanced Over 12 Months in the CHF-CePPORT Trial. Canadian Journal of Cardiology 34, S148-S149 (2018). https://doi.org:10.1016/j.cjca.2018.07.184

Fishbane S, Agoritsas S, Bellucci A, Halinski C, Shah HH, Sakhiya V, Balsam L. Augmented Nurse Care Management in CKD Stages 4 to 5: A Randomized Trial. Am J Kidney Dis. 2017 Oct;70(4):498-505. doi: 10.1053/j.ajkd.2017.02.366. Epub 2017 Apr 7. — View Citation

Foundation, K. Living with Kidney Failure, <https://kidney.ca/Kidney-Health/Living-With-Kidney-Failure> (

Garcia-Lizana F, Sarria-Santamera A. New technologies for chronic disease management and control: a systematic review. J Telemed Telecare. 2007;13(2):62-8. doi: 10.1258/135763307780096140. — View Citation

Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, Go AS, Chertow GM. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005 Dec;68(6):2801-8. doi: 10.1111/j.1523-1755.2005.00752.x. — View Citation

Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, Yusuf S, Michelson EL, Pfeffer MA; CHARM investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005 Dec 10;366(9502):2005-11. doi: 10.1016/S0140-6736(05)67760-4. — View Citation

Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019 Jul;95:103208. doi: 10.1016/j.jbi.2019.103208. Epub 2019 May 9. — View Citation

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30. — View Citation

Hays, R. D. et al. Kidney disease quality of life short form (KDQOL-SF™), version 1.3: a manual for use and scoring. Santa Monica, CA: Rand 7994 (1997).

He T, Liu X, Li Y, Wu Q, Liu M, Yuan H. Remote home management for chronic kidney disease: A systematic review. J Telemed Telecare. 2017 Jan;23(1):3-13. doi: 10.1177/1357633X15626855. Epub 2016 Jul 9. — View Citation

Hung CS, Lee J, Chen YH, Huang CC, Wu VC, Wu HW, Chuang PY, Ho YL. Effect of Contract Compliance Rate to a Fourth-Generation Telehealth Program on the Risk of Hospitalization in Patients With Chronic Kidney Disease: Retrospective Cohort Study. J Med Internet Res. 2018 Jan 24;20(1):e23. doi: 10.2196/jmir.8914. — View Citation

Hunting G, Shahid N, Sahakyan Y, Fan I, Moneypenny CR, Stanimirovic A, North T, Petrosyan Y, Krahn MD, Rac VE. A multi-level qualitative analysis of Telehomecare in Ontario: challenges and opportunities. BMC Health Serv Res. 2015 Dec 9;15:544. doi: 10.1186/s12913-015-1196-2. — View Citation

Information, C. I. f. H. Annual statistics on organ replacement in Canada, 2011 to 2020. (2021).

Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014 May;63(5):713-35. doi: 10.1053/j.ajkd.2014.01.416. Epub 2014 Mar 16. — View Citation

Kasser, T., & Ryan, R. M. Aspiration Index [Database record]. APA PsycTests (1993).

Khaw KT, Wareham N, Bingham S, Welch A, Luben R, Day N. Combined impact of health behaviours and mortality in men and women: the EPIC-Norfolk prospective population study. PLoS Med. 2008 Jan 8;5(1):e12. doi: 10.1371/journal.pmed.0050012. Erratum In: PLoS Med. 2008 Mar 18;5(3):e70. — View Citation

Klarenbach S, Tonelli M, Pauly R, Walsh M, Culleton B, So H, Hemmelgarn B, Manns B. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. J Am Soc Nephrol. 2014 Mar;25(3):587-94. doi: 10.1681/ASN.2013040360. Epub 2013 Nov 14. — View Citation

Krahn MD, Bremner KE, de Oliveira C, Dixon SN, McFarlane P, Garg AX, Mitsakakis N, Blake PG, Harvey R, Pechlivanoglou P. Home Dialysis Is Associated with Lower Costs and Better Survival than Other Modalities: A Population-Based Study in Ontario, Canada. Perit Dial Int. 2019 Nov-Dec;39(6):553-561. doi: 10.3747/pdi.2018.00268. Epub 2019 Oct 3. — View Citation

Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. — View Citation

Kummervold PE, Chronaki CE, Lausen B, Prokosch HU, Rasmussen J, Santana S, Staniszewski A, Wangberg SC. eHealth trends in Europe 2005-2007: a population-based survey. J Med Internet Res. 2008 Nov 17;10(4):e42. doi: 10.2196/jmir.1023. — View Citation

Kutner NG, Zhang R, Huang Y, Wasse H. Patient awareness and initiation of peritoneal dialysis. Arch Intern Med. 2011 Jan 24;171(2):119-24. doi: 10.1001/archinternmed.2010.361. Epub 2010 Sep 27. — View Citation

Landreneau K, Lee K, Landreneau MD. Quality of life in patients undergoing hemodialysis and renal transplantation--a meta-analytic review. Nephrol Nurs J. 2010 Jan-Feb;37(1):37-44. — View Citation

Lin MY, Liu MF, Hsu LF, Tsai PS. Effects of self-management on chronic kidney disease: A meta-analysis. Int J Nurs Stud. 2017 Sep;74:128-137. doi: 10.1016/j.ijnurstu.2017.06.008. Epub 2017 Jun 21. — View Citation

Liu S, Tanaka R, Barr S, Nolan RP. Effects of self-guided e-counseling on health behaviors and blood pressure: Results of a randomized trial. Patient Educ Couns. 2020 Mar;103(3):635-641. doi: 10.1016/j.pec.2019.10.007. Epub 2019 Oct 19. — View Citation

Lorig KR, Sobel DS, Ritter PL, Laurent D, Hobbs M. Effect of a self-management program on patients with chronic disease. Eff Clin Pract. 2001 Nov-Dec;4(6):256-62. — View Citation

Ludlow MJ, George CR, Hawley CM, Mathew TH, Agar JW, Kerr PG, Lauder LA. How Australian nephrologists view home dialysis: results of a national survey. Nephrology (Carlton). 2011 May;16(4):446-52. doi: 10.1111/j.1440-1797.2010.01403.x. — View Citation

Manns B, Hemmelgarn B, Tonelli M, Au F, So H, Weaver R, Quinn AE, Klarenbach S; for Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease. The Cost of Care for People With Chronic Kidney Disease. Can J Kidney Health Dis. 2019 Apr 4;6:2054358119835521. doi: 10.1177/2054358119835521. eCollection 2019. — View Citation

Mendelssohn DC, Mujais SK, Soroka SD, Brouillette J, Takano T, Barre PE, Mittal BV, Singh A, Firanek C, Story K, Finkelstein FO. A prospective evaluation of renal replacement therapy modality eligibility. Nephrol Dial Transplant. 2009 Feb;24(2):555-61. doi: 10.1093/ndt/gfn484. Epub 2008 Aug 28. — View Citation

Milazi M, Bonner A, Douglas C. Effectiveness of educational or behavioral interventions on adherence to phosphate control in adults receiving hemodialysis: a systematic review. JBI Database System Rev Implement Rep. 2017 Apr;15(4):971-1010. doi: 10.11124/JBISRIR-2017-003360. — View Citation

Miller, W. R. & Rollnick, S. Motivational interviewing: Helping people change, 3rd edition. (Guilford Press, 2013).

Mitchell PH, Powell L, Blumenthal J, Norten J, Ironson G, Pitula CR, Froelicher ES, Czajkowski S, Youngblood M, Huber M, Berkman LF. A short social support measure for patients recovering from myocardial infarction: the ENRICHD Social Support Inventory. J Cardiopulm Rehabil. 2003 Nov-Dec;23(6):398-403. doi: 10.1097/00008483-200311000-00001. No abstract available. — View Citation

Network, O. R. Living with Chronic Kidney Disease, <https://www.ontariorenalnetwork.ca/en/kidney-care-resources/living-with-chronic-kidney-disease>

Nguyen NTQ, Cockwell P, Maxwell AP, Griffin M, O'Brien T, O'Neill C. Chronic kidney disease, health-related quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England. PLoS One. 2018 Nov 26;13(11):e0207960. doi: 10.1371/journal.pone.0207960. eCollection 2018. — View Citation

Nolan RP, Feldman R, Dawes M, Kaczorowski J, Lynn H, Barr SI, MacPhail C, Thomas S, Goodman J, Eysenbach G, Liu S, Tanaka R, Surikova J. Randomized Controlled Trial of E-Counseling for Hypertension: REACH. Circ Cardiovasc Qual Outcomes. 2018 Jul;11(7):e004420. doi: 10.1161/CIRCOUTCOMES.117.004420. — View Citation

Nolan RP, Liu S, Feldman R, Dawes M, Barr S, Lynn H, Gwardy-Sridhar F, Thomas SG, Goodman J, Oh P, Kaczorowski J, Chessex C, Hachinski V, Shoemaker K. Reducing risk with e-based support for adherence to lifestyle change in hypertension (REACH): protocol for a multicentred randomised controlled trial. BMJ Open. 2013 Aug 21;3(8):e003547. doi: 10.1136/bmjopen-2013-003547. — View Citation

Nolan RP, Payne AY, Ross H, White M, D'Antono B, Chan S, Barr SI, Gwadry-Sridhar F, Nigam A, Perreault S, Farkouh M, McDonald M, Goodman J, Thomas S, Zieroth S, Isaac D, Oh P, Rajda M, Chen M, Eysenbach G, Liu S, Zbib A. An Internet-Based Counseling Intervention With Email Reminders that Promotes Self-Care in Adults With Chronic Heart Failure: Randomized Controlled Trial Protocol. JMIR Res Protoc. 2014 Jan 30;3(1):e5. doi: 10.2196/resprot.2957. — View Citation

Nolan RP, Ross HJ, Farkouh ME, Huszti E, Chan S, Toma M, D'Antono B, White M, Thomas S, Barr SI, Perreault S, McDonald M, Zieroth S, Isaac D, Wielgosz A, Mielniczuk LM. Automated E-Counseling for Chronic Heart Failure: CHF-CePPORT Trial. Circ Heart Fail. 2021 Jan;14(1):e007073. doi: 10.1161/CIRCHEARTFAILURE.120.007073. Epub 2021 Jan 19. — View Citation

Payne AY, Surikova J, Liu S, Ross H, Mechetiuc T, Nolan RP. Usability Testing of an Internet-Based e-Counseling Platform for Adults With Chronic Heart Failure. JMIR Hum Factors. 2015 May 8;2(1):e7. doi: 10.2196/humanfactors.4125. — View Citation

Pechlivanoglou P, Abrahamyan L, MacKeigan L, Consiglio GP, Dolovich L, Li P, Cadarette SM, Rac VE, Shin J, Krahn M. Factors affecting the delivery of community pharmacist-led medication reviews: evidence from the MedsCheck annual service in Ontario. BMC Health Serv Res. 2016 Nov 21;16(1):666. doi: 10.1186/s12913-016-1888-2. — View Citation

Ryff CD. In the eye of the beholder: views of psychological well-being among middle-aged and older adults. Psychol Aging. 1989 Jun;4(2):195-201. doi: 10.1037//0882-7974.4.2.195. — View Citation

Scarpa MP, Zopluoglu C, Prilleltensky I. Assessing multidimensional mattering: Development and exploratory validation of the Mattering in Domains of Life Scale (MIDLS). J Community Psychol. 2022 Apr;50(3):1430-1453. doi: 10.1002/jcop.22725. Epub 2021 Oct 4. — View Citation

Sheldon, K. M. & Hilpert, J. C. The balanced measure of psychological needs (BMPN) scale: An alternative domain general measure of need satisfaction. Motivation and Emotion 36, 439-451 (2012). https://doi.org:10.1007/s11031-012-9279-4

Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006 Jul 1;333(7557):15. doi: 10.1136/bmj.38875.675486.55. Epub 2006 Jun 21. — View Citation

Slater M, Bielecki J, Alba AC, Abrahamyan L, Tomlinson G, Mak S, MacIver J, Zieroth S, Lee D, Wong W, Krahn M, Ross H, Rac VE. Comparative effectiveness of the different components of care provided in heart failure clinics-protocol for a systematic review and network meta-analysis. Syst Rev. 2019 Feb 2;8(1):40. doi: 10.1186/s13643-019-0953-4. — View Citation

Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev. 2014 Jun 18;(6):CD007333. doi: 10.1002/14651858.CD007333.pub2. — View Citation

Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. — View Citation

Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, Chodick G, Collins AJ, Djurdjev O, Elley CR, Evans M, Garg AX, Hallan SI, Inker LA, Ito S, Jee SH, Kovesdy CP, Kronenberg F, Heerspink HJ, Marks A, Nadkarni GN, Navaneethan SD, Nelson RG, Titze S, Sarnak MJ, Stengel B, Woodward M, Iseki K; CKD Prognosis Consortium. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. JAMA. 2016 Jan 12;315(2):164-74. doi: 10.1001/jama.2015.18202. Erratum In: JAMA. 2016 Feb 23;315(8):822. — View Citation

Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011 Apr 20;305(15):1553-9. doi: 10.1001/jama.2011.451. Epub 2011 Apr 11. — View Citation

Trinh E, Chan CT, Perl J. Dialysis modality and survival: Done to death. Semin Dial. 2018 Jul;31(4):315-324. doi: 10.1111/sdi.12692. Epub 2018 Mar 14. — View Citation

Trinh E, Hanley JA, Nadeau-Fredette AC, Perl J, Chan CT. A comparison of technique survival in Canadian peritoneal dialysis and home hemodialysis patients. Nephrol Dial Transplant. 2019 Nov 1;34(11):1941-1949. doi: 10.1093/ndt/gfz075. — View Citation

United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD).

Van Biesen W, van der Veer SN, Murphey M, Loblova O, Davies S. Patients' perceptions of information and education for renal replacement therapy: an independent survey by the European Kidney Patients' Federation on information and support on renal replacement therapy. PLoS One. 2014 Jul 31;9(7):e103914. doi: 10.1371/journal.pone.0103914. eCollection 2014. — View Citation

Vinson AJ, Perl J, Tennankore KK. Survival Comparisons of Home Dialysis Versus In-Center Hemodialysis: A Narrative Review. Can J Kidney Health Dis. 2019 Jul 13;6:2054358119861941. doi: 10.1177/2054358119861941. eCollection 2019. — View Citation

Walker AMN, Drozd M, Hall M, Patel PA, Paton M, Lowry J, Gierula J, Byrom R, Kearney L, Sapsford RJ, Witte KK, Kearney MT, Cubbon RM. Prevalence and Predictors of Sepsis Death in Patients With Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction. J Am Heart Assoc. 2018 Oct 16;7(20):e009684. doi: 10.1161/JAHA.118.009684. — View Citation

Walker RC, Hanson CS, Palmer SC, Howard K, Morton RL, Marshall MR, Tong A. Patient and caregiver perspectives on home hemodialysis: a systematic review. Am J Kidney Dis. 2015 Mar;65(3):451-63. doi: 10.1053/j.ajkd.2014.10.020. Epub 2015 Jan 10. — View Citation

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. — View Citation

Weddington, W. W., Jr. Facilitating Treatment Adherence: A Practitioner's Guidebook. JAMA 260, 273-273 (1988). https://doi.org:10.1001/jama.1988.03410020139051

Wong JV, Yang GJ, Auguste BL, Ong SW, Logan AG, Chan CT, Nolan RP. Automated Digital Counseling Program (ODYSSEE-Kidney Health): A Pilot Study on Health-Related Quality of Life. Kidney360. 2023 Oct 1;4(10):1397-1406. doi: 10.34067/KID.0000000000000229. Epub 2023 Aug 14. — View Citation

* Note: There are 75 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of home RRT	The primary objective is to determine whether an automated digital counselling program for CKD self-care and RRT education improves RRT or preemptive renal transplant over a median of 19 months. As in our previous research,45-47 assessment of RRT includes documentation of incident home dialysis (HPD or HHD) or preemptive kidney transplant (before dialysis) in a composite index, using data from the Canadian Institute for Health Information (CIHI).48	Trial completion (median = 19 months, range = 12-27 months)
Secondary	Improvement of Home RRT	The secondary objective is to determine whether an automated digital counselling program for CKD self-care and RRT education improves home RRT (measured by a composite index of documented HHD, HPD, or pre-emptive kidney transplantation)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Improvement of RRT preparation with planned dialysis access	RRT preparation with planned dialysis access, based on the incidence of arteriovenous fistula (AVF), arteriovenous graft (AVG), or peritoneal dialysis (PD) catheter	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Incidence of annual hospitalization rate	Obtained using CIHI databases,48 assessed as the rate, per patient, per year, and defined from date of randomization to the earliest of death, start of dialysis	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Engagement with RRT education and CKD self-care counselling resources	Measured by the sum of logons, sum of logon hours, and number of logon days prior to a logon lapse of equal to or greater than 1 month (data is obtained using backend analytic tools of ODYSSEE, as in CHF-CePPORT49-52 and the previous pilot study)53-55	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported engagement in activities for living well	Evaluation of Goal-Directed Activities to Promote Well-Being and Health (EUROIA), developed by the principal investigator	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported assessment for health-related quality of life due to kidney disease	36-Item Kidney Disease Quality of Life - Short Form (KDQOL-SF)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported assessment of people's aspirations and goals	Aspirations Index (AI)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported measure of overall health (e.g. pain, mental health, physical, role and social functioning)	36-Item Short Form (SF-36)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported depression	9-Item Patient Health Questionnaire (PHQ-9)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported perceived social support	ENRICHD Social Support Instrument (ESSI)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported psychological wellbeing	Flourishing Scale (FS)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported anxiety	7-Item Generalized Anxiety Disorder instrument (GAD-7)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported feeling of value to self and others	9-Item Mattering in Domains of Life Scale (MIDLS)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported measure of psychological wellbeing and happiness	18-Item Psychological Wellbeing Scale (PWB)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported measure of overall life experience	18-Item Balanced Measure of Psychological Needs (BMPN)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported measure of well-being	WHO-5 Item Well-Being Index	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported readiness for change (motivation)	Patient-reported readiness to initiate renal replacement therapy	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)
Secondary	Self-reported confidence in doing life activities	Self-Efficacy for Managing Chronic Diseases 6-item Scale (SEMCD-6)	Month 6, month 12, Trial completion (median = 19 months, range = 12-27 months)

External Links

•   Syed, F., Stogios, N., Huszti, E., et al. An assessment of goal-directed behaviours aimed at improving HRQL using the Evaluation of goal-directed behaviours to promote well being and health (EUROIA) Scale: A proof-of-concept study. CJC 38, 154-155 (2022)